These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 2721547)

  • 1. N alpha-acetyl-[Arg8]vasopressin antagonizes the behavioral effect of [Cyt6]vasopressin-(5-9), but not of vasopressin.
    Kovács GL; Liu B; Burbach JP; Van Ree JM; De Wied D
    Eur J Pharmacol; 1989 Feb; 161(1):27-35. PubMed ID: 2721547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactive effects of neurohypophyseal neuropeptides with receptor antagonists on passive avoidance behavior: mediation by a cerebral neurohypophyseal hormone receptor?
    de Wied D; Elands J; Kovács G
    Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1494-8. PubMed ID: 1847526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facilitation of avoidance behavior by vasopressin fragments microinjected into limbic-midbrain structures.
    Kovács GL; Veldhuis HD; Versteeg DH; De Wied D
    Brain Res; 1986 Apr; 371(1):17-24. PubMed ID: 3708341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure activity relationship studies with C-terminal fragments of vasopressin and oxytocin on avoidance behaviors of rats.
    de Wied D; Gaffori O; Burbach JP; Kovács GL; van Ree JM
    J Pharmacol Exp Ther; 1987 Apr; 241(1):268-74. PubMed ID: 3572787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopressin antagonists block peripheral as well as central vasopressin receptors.
    De Wied D; Gaffori O; Van Ree JM; De Jong W
    Pharmacol Biochem Behav; 1984 Sep; 21(3):393-400. PubMed ID: 6093152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Passive avoidance behavior, vasopressin and the immune system. A link between avoidance latency and immune response.
    Croiset G; Heijnen CJ; de Wied D
    Neuroendocrinology; 1990 Feb; 51(2):156-61. PubMed ID: 2106096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-lasting enhancement of synaptic excitability of CA1/subiculum neurons of the rat ventral hippocampus by vasopressin and vasopressin(4-8).
    Chepkova AN; French P; De Wied D; Ontskul AH; Ramakers GM; Skrebitski VG; Gispen WH; Urban IJ
    Brain Res; 1995 Dec; 701(1-2):255-66. PubMed ID: 8925289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arginine vasopressin and a vasopressin antagonist peptide: opposite effects on extinction of active avoidance in rats.
    Koob GF; Le Moal M; Gaffori O; Manning M; Sawyer WH; Rivier J; Bloom FE
    Regul Pept; 1981 Jun; 2(3):153-63. PubMed ID: 7255768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of centrally injected AVP on heart rate, core temperature, and behavior in rats.
    Diamant M; De Wied D
    Am J Physiol; 1993 Jan; 264(1 Pt 2):R51-61. PubMed ID: 8430886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antagonism of effects of vasopressin (AVP) on inhibitory avoidance by a vasopressin antagonist peptide [dPtyr(Me)AVP].
    LeBrun CJ; Rigter H; Martinez JL; Koob GF; Le Moal M; Bloom FE
    Life Sci; 1984 Oct; 35(14):1505-12. PubMed ID: 6482669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the vasopressin-enhancing effect on memory retrieval and relearning by a vasopressin V1 receptor antagonist in mice.
    Alescio-Lautier B; Rao H; Paban V; Devigne C; Soumireu-Mourat B
    Eur J Pharmacol; 1995 Dec; 294(2-3):763-70. PubMed ID: 8750743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of enhanced cerebrospinal fluid levels of vasopressin, vasopressin antagonist or vasoactive intestinal polypeptide on circadian sleep-wake rhythm in the rat.
    Kruisbrink J; Mirmiran M; Van der Woude TP; Boer GJ
    Brain Res; 1987 Sep; 419(1-2):76-86. PubMed ID: 3676743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopressin, vasopressin fragments and a C-terminal peptide of the vasopressin precursor share cardiovascular effects when microinjected into the nucleus tractus solitarii.
    Brattström A; De Jong W; Burbach JP; De Wied D
    Psychoneuroendocrinology; 1989; 14(6):461-7. PubMed ID: 2623134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of intrathecal vasopressin-induced antinociception, scratching behavior, and motor suppression.
    Thurston CL; Campbell IG; Culhane ES; Carstens E; Watkins LR
    Peptides; 1992; 13(1):17-25. PubMed ID: 1535707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative light microscopic autoradiographic localization of binding sites labelled with [3H]vasopressin antagonist d(CH2)5Tyr(Me)VP in the rat brain, pituitary and kidney.
    van Leeuwen FW; van der Beek EM; van Heerikhuize JJ; Wolters P; van der Meulen G; Wan YP
    Neurosci Lett; 1987 Sep; 80(2):121-6. PubMed ID: 2960918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonally active arginine-vasopressin suppresses endotoxin-induced fever in rats: lack of effect of oxytocin and a behaviorally active vasopressin fragment.
    Kovács GL; De Wied D
    Neuroendocrinology; 1983 Oct; 37(4):258-61. PubMed ID: 6355890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of vasopressin analog [d(CH2)1(5),Tyr(Me)2]AVP on learning and memory in rats chronically treated with ethanol.
    Car H; Borawska MH; Wiśniewski K
    Pol J Pharmacol; 1993; 45(5-6):503-12. PubMed ID: 8012473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of vasopressin, oxytocin and peptides derived from these hormones on field potential induced in lateral septum of rats by stimulation of the fimbria fornix.
    Urban IJ; De Wied D
    Neuropeptides; 1986 Jan; 7(1):41-9. PubMed ID: 3951680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proconvulsive effect of vasopressin; mediation by a putative V2 receptor subtype in the central nervous system.
    Croiset G; De Wied D
    Brain Res; 1997 Jun; 759(1):18-23. PubMed ID: 9219858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopressin analgesia: specificity of action and non-opioid effects.
    Kordower JH; Bodnar RJ
    Peptides; 1984; 5(4):747-56. PubMed ID: 6494025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.